What Clinical Supply Chain Audits Cover
The clinical supply chain extends from manufacturing through packaging, labeling, storage, distribution, and finally to the investigator site where the product is dispensed or administered. Each step introduces risks to product quality, traceability, and blinding. A GMP audit for the clinical supply chain assesses whether these risks are controlled end to end.
The scope includes the manufacturing site, the packaging and labeling operation, the storage facilities, the distribution partners, and the investigator site handling. It also covers the systems that support traceability, temperature control, and accountability.
Also read: GMP Audit for ATMPs: Advanced Therapy Medicinal Products
The Regulatory Context
EU GMP Annex 13 and Annex 16
Annex 13 of EudraLex Volume 4 covers investigational medicinal products. Annex 16 covers the certification by a Qualified Person and batch release. Together they set requirements for the clinical supply chain in the EU.
EU GDP and Clinical Trials
Good Distribution Practice requirements apply to the distribution of IMPs. Temperature control, traceability, and handling are part of the expectations.
FDA 21 CFR Part 312 and 21 CFR 211
The FDA requires that investigational drugs be manufactured, handled, and distributed in accordance with cGMP and the investigational new drug regulations.
ICH GCP E6 and Investigational Product Handling
ICH GCP requires that investigational products are handled and stored according to the protocol and the sponsor’s instructions, and that accountability is maintained at the site.
Health Canada and MHRA
Health Canada and the MHRA regulate clinical trials and have expectations for IMP handling, storage, and distribution.
What Audits Focus On
Manufacturing and Release
Manufacturing should meet GMP requirements appropriate to the phase. Release and certification should be performed by authorized persons.
Packaging and Labeling
Labels should meet protocol and regulatory requirements. Blinding should be maintained. Packaging should protect the product.
Storage
Storage conditions should be defined and monitored. Temperature excursions should be investigated.
Distribution
Distribution partners should be qualified. Temperature control during shipping should be validated. Traceability should be maintained.
Investigator Site Handling
Sites should store and handle product according to the protocol. Accountability should be documented. Temperature monitoring should be in place where required.
Returns and Destruction
Returns and destruction should be documented and controlled. Accountability should be reconciled.
Traceability and Accountability
The chain from manufacturing to site should be traceable. Accountability records should reconcile.
Systems and Documentation
Systems that support traceability and temperature monitoring should be validated. Documentation should be complete.
Common Findings in Clinical Supply Chain Audits
Temperature Excursions Not Investigated
Accountability Records That Do Not Reconcile
Distribution Partner Qualification Gaps
Investigator Site Storage Gaps
Blinding Breaches
Returns and Destruction Documentation Gaps
Traceability Gaps
Introducing GxP Cellators for Clinical Supply Chain Audits
GxP Cellators provides GMP audits for the clinical supply chain covering manufacturing, packaging and labeling, storage, distribution, investigator site handling, returns and destruction, traceability and accountability, and supporting systems.
We work across FDA, EMA, Health Canada, MHRA, WHO, and PIC/S frameworks, and we adapt the audit scope to the phase and the supply chain design. Our auditors bring regulatory inspection and industry quality experience, and we deliver clear, prioritized reports with practical remediation guidance.
We also provide supplier and vendor audits for distribution partners and mock inspections for sites preparing for inspection.
Protect Your Clinical Supply Chain
Visit https://www.gxpcellators.com/gmp-auditing/ for service details. Email or use https://www.gxpcellators.com/contact/ to discuss your clinical supply chain audit.
Frequently Asked Questions About Clinical Supply Chain Audits
What is Annex 13?
Annex 13 of EudraLex Volume 4 covers the manufacture of investigational medicinal products in the EU.
What is Annex 16?
Annex 16 covers the certification by a Qualified Person and batch release, including for investigational medicinal products.
How do you assess temperature control during distribution?
We review shipping validation, temperature monitoring, and excursion investigation to confirm that control is maintained.
What is accountability in clinical trials?
Accountability is the documentation of what product was received, dispensed, returned, and destroyed at the site. It should reconcile.
Do you audit investigator sites?
We can audit investigator site handling as part of the supply chain audit, focusing on storage, accountability, and protocol compliance.
Can you help us prepare for an inspection of our clinical supply chain?
Yes. We conduct readiness reviews and mock inspections that simulate the questions an inspector would ask.
How do I request a clinical supply chain audit?
Email or use https://www.gxpcellators.com/contact/. Service details are at https://www.gxpcellators.com/gmp-auditing/.
